Blase Polite to Antineoplastic Agents
This is a "connection" page, showing publications Blase Polite has written about Antineoplastic Agents.
Connection Strength
1.252
-
Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change. JAMA Oncol. 2021 01 01; 7(1):25-26.
Score: 0.309
-
Reply to M. Thompson et Al. J Oncol Pract. 2015 May; 11(3):263-4.
Score: 0.206
-
Payment for oncolytics in the United States: a history of buy and bill and proposals for reform. J Oncol Pract. 2014 Nov; 10(6):357-62.
Score: 0.201
-
Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer. 2012 Feb 15; 118(4):1083-90.
Score: 0.161
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
Score: 0.064
-
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017 06 20; 317(23):2392-2401.
Score: 0.060
-
Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 04; 18(4):446-453.
Score: 0.059
-
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
Score: 0.048
-
Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
Score: 0.044
-
Infused chemotherapy use in the elderly after patent expiration. Am J Manag Care. 2012 May 01; 18(5):e173-8.
Score: 0.042
-
Value-based insurance design in oncology. Lancet Oncol. 2011 Apr; 12(4):321-3.
Score: 0.039
-
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.
Score: 0.018